NBIO

Nascent Biotech, Inc. [NBIO] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

NBIO Stock Summary

Top 10 Correlated ETFs

NBIO


Top 10 Correlated Stocks

NBIO


In the News

08:00 29 Mar 2024 NBIO

Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting

NORTH PALM BEACH, FL / ACCESSWIRE / May 9, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space, announced today that the Company has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting held in Chicago on June 2-6, 2023. The poster presentation, entitled "Phase I Study of Pritumumab in Brain Cancer", will take place from 1:15-4:15 PM CDT on June 3rd, during the "Central Nervous Systems Tumors" session in Hall A of McCormick Place Convention Center.

08:00 29 Mar 2024 NBIO

Nascent Biotech and Manhattan BioSolutions Announce Promising Prelim/Preclinical Results in BCG-Based COVID-19 Vaccine Research Collaboration

SAN DIEGO, CA / ACCESSWIRE / July 13, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a biotechnology company pioneering innovative medicines to overcome difficult-to-treat cancers and viral infections, and its collaboration partner, Manhattan BioSolutions (together, the "Partners"), are pleased to announce promising new preliminary preclinical results for the COVID-19 vaccine candidate now progressing under joint development by the Partners. Under a research collaboration agreement signed in 2020, Nascent Biotech and Manhattan BioSolutions partnered to discover and develop a safe and affordable COVID-19 vaccination platform based on modifying licensed BCG vaccine technology originally developed for Tuberculosis ("TB"), but with broader utility in protecting against infection from other types of viruses, some of which may have the potential to cause major outbreaks in humans.

08:00 29 Mar 2024 NBIO

Marble Arch Research Publishes Analyst Research Report on Nascent Biotech

VERO BEACH, FL / ACCESSWIRE / June 15, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to highlight the publication of an in-depth analyst research report on Nascent Biotech by equity research firm, Marble Arch Research, Inc, which rated NBIO a "Speculative Buy" under its tiered rating system, and specified a price target of between $0.39-$1.99. The full research report may be found at: https://www.nascentbiotech.com/wp-content/uploads/2021/06/marble-arch-report-6.10.21.pdf The report concludes, "We believe that there is a reasonable investment thesis at hand to indicate that the company's market value can rise significantly as its lead development drug, PTB, progresses through its clinical study journey, which has just begun.

11:15 29 Mar 2024 NBIO

Week In Review: LianBio Acquires 2 IBD Candidates In $218 Million Deal

LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. Ji Xing Pharma of Shanghai acquired Greater China rights to a novel treatment for tachycardia from Milestone Pharma in a $127.5 million agreement.

08:00 29 Mar 2024 NBIO

Nascent Biotech and BioRay Pharmaceutical Announce $5,000,000 Exclusive License Agreement for Development and Commercialization of Nascent's Pritumumab

TAIZHOU, ZHEJIANG, CHINA & SAN DIEGO, CA / ACCESSWIRE / May 19, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) and BioRay Pharmaceutical Ltd., today announced that Nascent Biotech ("Nascent" or the "Company") has entered into a license agreement (the "Agreement") with BioRay Pharmaceutical Co Ltd ("BioRay"), thereby granting to BioRay exclusive rights to commercialize Nascent's monoclonal antibody, Pritumumab, in international markets, excluding North America and Central America.

08:00 29 Mar 2024 NBIO

Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note

SAN DIEGO, CA / ACCESSWIRE / May 4, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce further strides toward the elimination of toxic debt and dilution risk with the preemptive settlement of its outstanding convertible note liability (the "Note") held by Harbor Gate Capital LLC ("Harbor Gate"). Under the terms of the Note, Harbor Gate had the right to redeem the outstanding liability in the form of an equity conversion that presented dilution risk for Nascent shareholders.

08:00 29 Mar 2024 NBIO

Nascent Biotech Announces Pre-emptive Elimination of Significant Tranche of Convertible Debt

SAN DIEGO, CA / ACCESSWIRE / April 26, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that It has paid off and eliminated a major convertible debt note, pre-emptively preventing a dilutive conversion. The note, which was held by JSJ Investments, LLC ("JSJ"), represented over $186k in debt carried pre-conversion on the Company's balance sheet.

08:00 29 Mar 2024 NBIO

Nascent Biotech Announces Initial Dosing Underway in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

SAN DIEGO, CA / ACCESSWIRE / March 31, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech," "Nascent," or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that patients have been enrolled and initial dosing has begun in the Company's landmark Phase I trial to evaluate Pritumumab ("PTB") as a treatment option for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases. Patient enrollment remains open, and the trial continues to recruit new patients for participation.

08:00 29 Mar 2024 NBIO

Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer

SAN DIEGO, CA / ACCESSWIRE / March 24, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the Company has officially opened its Phase I trial to evaluate Pritumumab (PTB), the Company's lead Monoclonal Antibody (Mab) therapeutic asset, as a treatment option for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases. Screening to enroll patients in the trial is already underway.

08:00 29 Mar 2024 NBIO

Nascent Biotech Earns US Patent for Crossing Blood-Brain Barrier

SAN DIEGO, CA / ACCESSWIRE / March 2, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is excited to announce that the Company has officially received allowance for a "Method-of-Use" patent by the US Patent and Trademark Office ("USPTO") for their primary asset, Pritumumab ("PTB"). Specifically, the patent approval is related to PTB's ability to cross the Blood-Brain Barrier ("BBB").

NBIO Financial details

Company Rating
Neutral
Market Cap
30.72M
Income
-2.09M
Revenue
0
Book val./share
0
Cash/share
0
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
14 Feb 2024
P/E
-6.97
Forward P/E
-
PEG
-0.07
P/S
-
P/B
-3358.67
P/C
-
P/FCF
-15.97
Quick Ratio
0.96
Current Ratio
0.99
Debt / Equity
4.12
LT Debt / Equity
-
-
-
EPS (TTM)
-0.01
EPS next Y
-
EPS next Q
1.58
EPS this Y
1585.71%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-78.57%
-
-
-
-
SMA20
60%
SMA50
6.67%
SMA100
6.67%
Inst Own
0.08%
Inst Trans
0.85%
ROA
-296%
ROE
323%
ROC
368.84%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
169.73M
Shs Float
93.93M
-
-
-
-
Target Price
-
52W Range
0.0323-0.28
52W High
-
52W Low
-
RSI
70.33
Rel Volume
0.5
Avg Volume
73.56K
Volume
36.52K
Perf Week
34.67%
Perf Month
54.65%
Perf Quarter
96.28%
Perf Half Y
39.25%
-
-
-
-
Beta
-3.247
-
-
Volatility
0.02%, 0.03%
Prev Close
13.02%
Price
0.1845
Change
11.48%

NBIO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-03-31

Metric History 2019-03-312020-03-312021-03-312022-03-31 2023-03-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
000.010.010
Net income per share
-0.05-0.12-0.020-0.02
Operating cash flow per share
-0.02-0.02-0.010-0.02
Free cash flow per share
-0.02-0.02-0.010-0.02
Cash per share
00000
Book value per share
-0.02-0.08-0.01-0.01-0.01
Tangible book value per share
-0.02-0.08-0.01-0.01-0.01
Share holders equity per share
-0.02-0.08-0.01-0.01-0.01
Interest debt per share
00.010.0100.02
Market cap
5.39M9.22M4.49M6.14M6.67M
Enterprise value
5.25M9.35M4.65M6.05M6.89M
P/E ratio
-3.93-2.25-3.41-41.58-2.38
Price to sales ratio
005.986.140
POCF ratio
-7.57-16.63-4.5514.85-3.73
PFCF ratio
-7.57-16.63-4.5514.85-3.73
P/B Ratio
-11.17-3.21-9.49-9.15-5.15
PTB ratio
-11.17-3.21-9.49-9.15-5.15
EV to sales
006.196.050
Enterprise value over EBITDA
-3.84-2.71-3.27-9.94-3.19
EV to operating cash flow
-7.38-16.87-4.7114.62-3.85
EV to free cash flow
-7.38-16.87-4.7114.62-3.85
Earnings yield
-0.25-0.44-0.29-0.02-0.42
Free cash flow yield
-0.13-0.06-0.220.07-0.27
Debt to equity
0-0.05-0.340-0.3
Debt to assets
043.140.2201.53
Net debt to EBITDA
0.1-0.04-0.110.16-0.1
Current ratio
0.2100.610.140.16
Interest coverage
0-39.79-4.16-1.36-1.25
Income quality
0.520.141.03-0.880.64
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
002.440.930
Research and developement to revenue
000.430.20
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
001.050.120
Graham number
0.130.470.050.010.08
ROIC
2.841.296.180.214.26
Return on tangible assets
-10.41-1.27K-1.75-1.4-10.98
Graham Net
-0.02-0.08-0.01-0.01-0.01
Working capital
-482.16K-2.88M-472.51K-671.48K-1.3M
Tangible asset value
-482.16K-2.88M-472.51K-671.48K-1.3M
Net current asset value
-482.16K-2.88M-472.51K-671.48K-1.3M
Invested capital
0-0.05-0.340-0.3
Average receivables
00375K375K0
Average payables
364.5K689.15K744.75K706.86K637.51K
Average inventory
00000
Days sales outstanding
0036500
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00100
Payables turnover
00000
Inventory turnover
00000
ROE
2.841.422.780.222.16
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q3

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.0100-0.010
Operating cash flow per share
-0.010000
Free cash flow per share
-0.010000
Cash per share
0000.010
Book value per share
-0.01-0.01-0.0100
Tangible book value per share
-0.01-0.01-0.0100
Share holders equity per share
-0.01-0.01-0.0100
Interest debt per share
0.010.01000
Market cap
23.9M7.2M6.98M18.68M28.92M
Enterprise value
23.81M7.42M7.25M17.98M28.42M
P/E ratio
-4.98-3.48-3.23-5.63-35.19
Price to sales ratio
00000
POCF ratio
-38.35-18.64-42.92-54.69-87.6
PFCF ratio
-38.35-18.64-42.92-54.69-87.6
P/B Ratio
-17.52-5.56-6.05-2.91K952.24
PTB ratio
-17.52-5.56-6.05-2.91K952.24
EV to sales
00000
Enterprise value over EBITDA
-50.14-13.75-14.16-21.48-77.98
EV to operating cash flow
-38.21-19.2-44.57-52.65-86.08
EV to free cash flow
-38.21-19.2-44.57-52.65-86.08
Earnings yield
-0.05-0.07-0.08-0.04-0.01
Free cash flow yield
-0.03-0.05-0.02-0.02-0.01
Debt to equity
-0.34-0.3-0.24-47.584.12
Debt to assets
0.831.533.510.290.19
Net debt to EBITDA
0.19-0.4-0.520.841.37
Current ratio
0.290.160.060.991.05
Interest coverage
-0.73-1.35-2.15-6.69-14.64
Income quality
0.740.750.30.411.61
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
0.050.030.0300
ROIC
0.7600.84-3.23-2.35
Return on tangible assets
-2.12-2.03-6.85-0.8-0.32
Graham Net
-0.01-0.01-0.0100
Working capital
-1.36M-1.3M-1.16M-6.41K30.37K
Tangible asset value
-1.36M-1.3M-1.16M-6.41K30.37K
Net current asset value
-1.36M-1.3M-1.16M-6.41K30.37K
Invested capital
-0.34-0.3-0.24-47.584.12
Average receivables
00000
Average payables
576.05K442.69K571.19K577.17K496.92K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
0.880.40.47129.4-6.76
Capex per share
00000

NBIO Frequently Asked Questions

What is Nascent Biotech, Inc. stock symbol ?

Nascent Biotech, Inc. is a US stock , located in Vero beach of Fl and trading under the symbol NBIO

What is Nascent Biotech, Inc. stock quote today ?

Nascent Biotech, Inc. stock price is $0.1845 today.

Is Nascent Biotech, Inc. stock public?

Yes, Nascent Biotech, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap